# Cardiotoxicity from cancer treatment

Condition · id `cardio:cardiotoxicity-from-cancer-treatment` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

Also called: Cancer therapy-related cardiovascular toxicity; Cardiotoxicity

Browse, organ or system: Heart  
Browse, condition area: Heart failure  

## In plain language

Cardiotoxicity from cancer treatment means damage to the heart or its function caused by cancer treatments such as chemotherapy, immunotherapy or radiation. A 2025 review says these treatments have increased survival but are frequently linked to cardiovascular toxicity, which has a significant impact on outcomes and well-being. The review says the changes can lead to conditions such as cardiomyopathy and can result in heart failure and sudden cardiac death.

## Technical summary

MeSH Cardiotoxicity (D066126) is recorded as a broad match: its scope note covers damage to the heart from toxic substances, including chemotherapy, immunotherapy and radiation, and is not limited to cancer care. The description rests on that scope note and on a 2025 review under a CC BY licence (Heart Failure Reviews). The review says there is no universally accepted definition and that the condition is often defined clinically as a reduction in left ventricular ejection fraction. Drug names, risk factors, monitoring and protective strategies in the review are not repeated here. The evidence is descriptive and comes from a narrative review, with no trial data.

## Claims, with the population each applies to

## Context: People treated for cancer with chemotherapy, targeted therapy, immunotherapy or radiotherapy (narrative review)

Recipient: Recipient not specified; Population: People who have had cancer treatment such as chemotherapy, targeted therapy, immunotherapy or radiotherapy, as the review describes them. The review also mentions long-term studies of childhood cancer survivors.; Care setting: Cancer treatment and cardio-oncology care, as described in the review.; Geography: Not stated for the review as a whole.; Life stage: Adults and children are not separated here. This record makes no statement about pregnancy, newborns or children.; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (a description of a condition).

### MeSH describes cardiotoxicity as damage to the heart or its function after exposure to toxic substances such as chemotherapy drugs, immunotherapy or radiation. A 2025 narrative review (Heart Failure Reviews) says cancer treatments are frequently linked to cardiovascular toxicity with a significant impact on clinical outcomes and well-being, that there is no universally accepted definition of the condition (it is often defined clinically as a reduction in left ventricular ejection fraction), and that the changes can lead to dilated and restrictive cardiomyopathy and can result in heart failure and sudden cardiac death.

- Category: Description
- Evidence stage: Evidence synthesis
- Certainty: Certainty not assessed
- Applies to: Recipient: Recipient not specified; Population: People who have had cancer treatment such as chemotherapy, targeted therapy, immunotherapy or radiotherapy, as the review describes them. The review also mentions long-term studies of childhood cancer survivors.; Care setting: Cancer treatment and cardio-oncology care, as described in the review.; Geography: Not stated for the review as a whole.; Life stage: Adults and children are not separated here. This record makes no statement about pregnancy, newborns or children.; Gestational age: Not reported; Postnatal age: Not reported; Follow-up: Not applicable (a description of a condition).
- Limitations: A narrative review and a thesaurus scope note, not a study of how often the damage occurs. The MeSH descriptor is not limited to cancer care. The review gives no risk figures here: its drug names, mechanisms, risk estimates, classification, monitoring and protective strategies are not repeated, and nothing here says who should be monitored or how.
- Last checked: 2026-11-18
- Sources:
  1. Supports: MeSH scope note for descriptor D066126 (Cardiotoxicity) (Dataset, edition MeSH linked-data record of the preferred concept M0592728 of descriptor D066126, fetched 2026-11-18. The scope note is on this concept record, not on the descriptor record.) <https://id.nlm.nih.gov/mesh/M0592728>
     Locator: scopeNote.@value, sentence 1. Retrieved 2026-11-18T18:06:08Z. Source state: Current. Version fingerprint: f80e554a493c601a68a23f9ff8b6f60bc0310dc074bd769961c0d895b865f807.
     How it applies: MeSH scope note: heart damage from chemotherapy, immunotherapy or radiation.
  2. Supports: Cancer therapy-induced cardiotoxicity: mechanisms and mitigations (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (Heart Failure Reviews, 2025), fetched 2026-11-18. A narrative or literature review. Used only for how the review defines cardiotoxicity from cancer treatment, what it links to and what it says about the heart conditions that can follow; its drug names, mechanisms, risk figures and cardioprotective strategies are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC12297282/>
     Locator: Abstract, sentence 2. Retrieved 2026-11-18T18:09:51Z. Source state: Current. Version fingerprint: 1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c.
     How it applies: Cancer treatments are frequently linked to cardiovascular toxicity.
  3. Supports: Cancer therapy-induced cardiotoxicity: mechanisms and mitigations (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (Heart Failure Reviews, 2025), fetched 2026-11-18. A narrative or literature review. Used only for how the review defines cardiotoxicity from cancer treatment, what it links to and what it says about the heart conditions that can follow; its drug names, mechanisms, risk figures and cardioprotective strategies are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC12297282/>
     Locator: Introduction, para 2, sentence 2 (first part). Retrieved 2026-11-18T18:09:51Z. Source state: Current. Version fingerprint: 1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c.
     How it applies: No universally accepted definition.
  4. Supports: Cancer therapy-induced cardiotoxicity: mechanisms and mitigations (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (Heart Failure Reviews, 2025), fetched 2026-11-18. A narrative or literature review. Used only for how the review defines cardiotoxicity from cancer treatment, what it links to and what it says about the heart conditions that can follow; its drug names, mechanisms, risk figures and cardioprotective strategies are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC12297282/>
     Locator: Introduction, para 2, sentence 2 (second part). Retrieved 2026-11-18T18:09:51Z. Source state: Current. Version fingerprint: 1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c.
     How it applies: Often defined clinically as a fall in ejection fraction.
  5. Supports: Cancer therapy-induced cardiotoxicity: mechanisms and mitigations (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (Heart Failure Reviews, 2025), fetched 2026-11-18. A narrative or literature review. Used only for how the review defines cardiotoxicity from cancer treatment, what it links to and what it says about the heart conditions that can follow; its drug names, mechanisms, risk figures and cardioprotective strategies are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC12297282/>
     Locator: Abstract, sentence 5 (first part). Retrieved 2026-11-18T18:09:51Z. Source state: Current. Version fingerprint: 1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c.
     How it applies: The changes can lead to cardiomyopathy.
  6. Supports: Cancer therapy-induced cardiotoxicity: mechanisms and mitigations (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (Heart Failure Reviews, 2025), fetched 2026-11-18. A narrative or literature review. Used only for how the review defines cardiotoxicity from cancer treatment, what it links to and what it says about the heart conditions that can follow; its drug names, mechanisms, risk figures and cardioprotective strategies are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC12297282/>
     Locator: Abstract, sentence 5 (end). Retrieved 2026-11-18T18:09:51Z. Source state: Current. Version fingerprint: 1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c.
     How it applies: The conditions can result in heart failure and sudden cardiac death.
  7. Background: Cancer therapy-induced cardiotoxicity: mechanisms and mitigations (Publication, edition PMC Open Access subset full-text XML, from NCBI E-utilities (Heart Failure Reviews, 2025), fetched 2026-11-18. A narrative or literature review. Used only for how the review defines cardiotoxicity from cancer treatment, what it links to and what it says about the heart conditions that can follow; its drug names, mechanisms, risk figures and cardioprotective strategies are not used.) <https://pmc.ncbi.nlm.nih.gov/articles/PMC12297282/>
     Locator: Abstract, sentence 1. Retrieved 2026-11-18T18:09:51Z. Source state: Current. Version fingerprint: 1fd62c1ddd41f65aceb23e6c727e3a74174e9abddfb6e23d988bce38d5a34e2c.
     How it applies: Context: the treatments have increased survival.

## Connected pages

- Filed under this front: Medicines (`cardio:front-medicines`)
- A 2025 review says cancer treatment-related heart changes can lead to dilated and restrictive cardiomyopathy: Cardiomyopathy (heart muscle disease) (`cardio:cardiomyopathy`) [a claim, not a settled fact; see claim `cardio:claim-cardiotoxicity-cancer-treatment-review` and its context]
- A 2025 review says the conditions that follow can result in heart failure: Heart failure (`cardio:heart-failure`) [a claim, not a settled fact; see claim `cardio:claim-cardiotoxicity-cancer-treatment-review` and its context]

## Provenance

Content hash: 236dbd27bff0068450a0e51859dfce956504cc6ac0bad57b5871f6434113cb8e
Last substantive edit: 2026-11-18
Evidence last checked: 2026-11-18
